LEO Innovation Lab showcases latest developments within AI and diagnosis

Share:
LinkedInFacebookTwitterEmail

LEO Innovation Lab will be showcasing the latest developments within its research into artificial intelligence (AI) and diagnosis at the Smart Country Convention in Berlin, November 20th-22nd 2018. This demonstration marks the flagship platform in a series of research initiatives investigating the potential for artificial intelligence (AI) in diagnosis, precision medicine and diseases prevention in chronic skin conditions. One such project is LEO Innovation Lab’s partnership with German biotech startup Biotx.ai.

Along with displaying the AI-platforms ability to diagnose skin conditions, (flagged by psoriasis to an accuracy degree of 91%), the Danish healthtech incubator will also be presenting its recommendations for how AI can augment the decision making of doctors, support precision medicine initiatives and alleviate the strain of chronic skin condition on public healthcare infrastructure.

 

Improving access to healthcare

In light of the growing shortage of healthcare workers – estimated to be at 12.9 million by 2035 – , the introduction of AI-assisted diagnosis can help alleviate strain by reducing the likelihood of inaccurate diagnosis and inappropriate referrals, hence augmenting doctors in the way medicine is being practiced today. This shortage is currently manifest in Germany, with labour unions reporting a need for 22 percent more hospital workers and a high level of inefficiency in comparison to neighbouring countries. For dermatology the issue is especially acute due to a low number of dermatologists, 5944, across the nation.

The incubators “Imagine” platform (https://getimagine.io/) combines an AI powered diagnosis arm, where skin conditions such as psoriasis, atopic dermatitis, acne and rosacea can be diagnosed through a smartphone image, with a tracking and progression arm that enable both patients and HCPs to track the development of skin flares over time. The combination of both augmented diagnosis and diseases monitoring over time is now being investigated as an approach to improve the life for patients with skin diseases and at the same time overall reduce the cost of managing chronic diseases.

A recent clinical study conducted between LEO Innovation Lab and Arbeitsgemeinschaft Dermatologische Prävention, Prof. Dr. med. Eckhard W. Breitbart, in Hamburg, with 37 general practitioners who all were exposed to thirty one patients with different skin diseases, and with the aid of a digital clinical decision support system the overall diagnostic accuracy was improved with amazing 34%, indicating the importance of augmenting the work of doctors to improve the overall outcomes with digital tools.

“Introducing more digital platforms such as Imagine into the healthcare infrastructure has the potential to address inefficiencies that patients experience today when interacting with the healthcare system.” said Kristian Hart-Hansen, CEO, LEO Innovation Lab. “Long waiting times, years of trial and errors with treatments and poor adherence due to lack of insights are all symptoms of an analogue system. By introducing digital solutions into the patient-healthcare interaction, we empower patients living with chronic conditions that need less physical interaction and are open to more digital interactions, thereby freeing up time and resources for healthcare workers to focus on the people most in need of treatment.”

 

Identifying Genetic SubTypes for Atopic Dermatitis with Biotx.ai

Biotx.ai employ machine learning techniques to analyse and identify complex interactive patterns in biomedical data. The process enables enables a the analysis of extremely large data sets, for example, analysing the human genome, a process that would take years if done manually, but can be shortened significantly through the application of a machine learning algorithm.

Through its partnership with Biotex.ai, LEO Innovation Lab is investigating the possibility of identifying subtypes of atopic dermatitis in the human genome; with a view to better understand the genetic triggers behind the disease. The goal is to provide patients with phenotypic information to help them better understand the triggers of their condition and also optimize what works to alleviate the symptoms for the individual.

LEO Innovation Lab will be participating in a panel discussion, as well as presenting their latest projects at the Smart Health Conference on Tuesday 20 November, 14h30-17h30.You can also pass by their stand at the Danish exhibition area.

 

Note to Editors

LEO Innovation Lab is an independent digital innovation unit established in 2015 by Denmark’s oldest pharmaceutical company, LEO Pharma. The unit focuses on digital health and has launched a wide range of digital solutions targeting patients worldwide. LEO Innovation Lab is an independent unit of LEO Pharma, established as part of a long-term strategic decision to focus on patient needs. The Innovation Lab does not develop medical treatments, but instead focuses on the aspects of everyday life that can affect people living with chronic skin conditions through digital health solution. The unit functions separately from its corporate mothership, to enable a start-up mindset and agile execution and has offices in Copenhagen, Tel Aviv, San Francisco, Shanghai and Toronto.

 

Contact

Copenhagen, Public Relations
Manita Dosanjh
Manita@leoilab.com
+45 31534592

RECENT PRESSRELEASES